Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation

British Journal of Ophthalmology

Volumn 94, Issue 7, 2010, Pages 864-870

  Baba, Takayuki ^a   Kubota Taniai, Mariko ^a   Kitahashi, Masayasu ^a   Okada, Kyoko ^a   Mitamura, Yoshinori ^a   Yamamoto, Shuichi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ARTICLE; COMPARATIVE STUDY; CORRELATION ANALYSIS; HUMAN; MYOPIA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA FOVEA; STATISTICAL SIGNIFICANCE; SUBRETINAL NEOVASCULARIZATION; THICKNESS; TREATMENT DURATION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ATROPHY; CHOROID; CHOROIDAL NEOVASCULARIZATION; HUMANS; INJECTIONS, INTRAOCULAR; MIDDLE AGED; MYOPIA; PHOTOCHEMOTHERAPY; RETINA; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 77954250541     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.166025     Document Type: Article

References (25)

1. Curtin BJ. The nature of pathologic myopia. In: Curtin BJ, ed. The myopias. Basic science and clinical management. Philadelphia, PA: Harper & Row, 1985:237-45.
2. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003;110:1297-305.
3. Secretan M, Kuhn D, Soubrane G, et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997;7:307-16. (Pubitemid 28042043)
4. Pece A, Brancato R, Avanza P, et al. Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int Ophthalmol 1994;18:339-44.
5. Brancato R, Pece A, Avanza P, et al. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina 1990;10:239-43.
6. Glacet-Bernard A, Benyelles N, Dumas S, et al. Photodynamic therapy vs limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study. Am J Ophthalmol 2007;143:68-76.
7. Hamelin N, Glacet-Bernard A, Brindeau C, et al. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol 2002;133:530-6.
8. Marticorena J, Gomez-Ulla F, Fernandez M, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am J Ophthalmol 2006;142:335-7.
9. Verteporfin in photodynamic therapy study group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin 1-year results of a randomized clinical trial-VIP report No.1. Ophthalmology 2001;108:841-52.
10. Verteporfin in photodynamic therapy study group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. 2-year results of randomized clinical trial-VIP report No.3. Ophthalmology 2003;110:667-73.
11. Ohno-Matsui K, Moriyama M, Hayashi K, et al. Choroidal vein and artery occlusion following photodynamic therapy in eyes with pathologic myopia. Graefe's Arch Exp Ophthalmol 2006;244:1363-6.
12. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: One-year results. Am J Ophthalmol 2009;147:94-100.
13. Gharbiya M, Allievi F, Mazzeo L, et al. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-months results. Am J Ophthalmol 2009;147:87-93.
14. Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 2009;23:2042-5.
15. Chan WM, Lai TY, Liu DT, et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150-4.
16. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, et al. Intravitreal bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009;93:448-51.
17. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009; 148:396-408.
18. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Photodynamic therapy with verteporphin for choroidal neovascularization of pathogenic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 2008;145:518-26.
19. Parodi M, DaPozzo S, Ravalico G. Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol Scand 2007;85:50-4.
20. Tokoro T. Types of fundus changes in the posterior pole. In: Tokoro T, ed. Atlas of posterior fundus changes in pathological myopia. Tokyo, Japan: Springer, 1998:5-22.
21. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003; 135:343-50.
22. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
23. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-4.
24. Peters S, Heiduschka P, Juliens S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
25. Kojima A, Ohno-Matsui K, Teramukai S, et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefe's Arch Clin Exp Ophthalmol 2006;244:1474-9.